PPA
KYMR icon

Parametric Portfolio Associates’s Kymera Therapeutics KYMR Stock Holding History

Parametric Portfolio Associates’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$952K Buy
22,494
+8,446
+60% +$357K ﹤0.01% 2804
2021
Q4 		$892K Buy
14,048
+270
+2% +$15.7K ﹤0.01% 2827
2021
Q3 		$809K Buy
13,778
+4,046
+42% +$235K ﹤0.01% 2894
2021
Q2 		$472K Buy
9,732
+4,114
+73% +$179K ﹤0.01% 3111
2021
Q1 		$218K Buy
+5,618
New +$338K ﹤0.01% 3842

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parametric Portfolio Associates's KYMR Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Kymera Therapeutics (KYMR) stake by 60% in Q1 2022, buying an estimated $357K and bringing the position to 22,494 shares worth $952K. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Parametric Portfolio Associates first reported a position in KYMR in Q1 2021 and has held it in 5 quarters since. 126 funds tracked by Wall St. Rank hold KYMR as of Q1 2022.

  • Parametric Portfolio Associates held 22,494 shares of Kymera Therapeutics worth $952K as of Q1 2022.
  • Parametric Portfolio Associates bought 8,446 Kymera Therapeutics shares in Q1 2022, an estimated $357K.
  • Kymera Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2804 holding.
  • Parametric Portfolio Associates first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 126 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.